## VTRS: Viatris Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 2.8% below STRENGTH zone (3.0-6.0%); RSI 72 overbought. Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.0% MRS), overbought RSI (72).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($11.31)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 2, Bearish: 2)

**1. Lost Money on Viatris Inc. (VTRS)? Join Class Action Before June 3, 2025 - Contact Levi & Korsinsky**
- Source: WJBF | 20251217T000854 | Bearish | Relevance: 100%
- Levi & Korsinsky LLP has filed a class action securities lawsuit against Viatris Inc. (NASDAQ: VTRS) for alleged securities fraud between August 8, 2024, and February 26, 2025. The lawsuit claims Viatris misrepresented the impact of an FDA warning letter, which led to a significant stock price decline after disappointing Q4 2024 financial results and 2025 guidance. Shareholders who suffered losses are encouraged to contact the firm to learn about their rights to recovery before June 3, 2025.

**2. Join Class Action to Recover Losses from Viatris Inc. (VTRS) - Contact Levi & Korsinsky Before June 3, 2025**
- Source: KTLA | 20251218T170848 | Bearish | Relevance: 100%
- Levi & Korsinsky LLP has announced a class action securities lawsuit against Viatris Inc. (VTRS) for shareholders who suffered losses between August 8, 2024, and February 26, 2025. The lawsuit alleges Viatris misrepresented the impact of an FDA warning letter concerning its Indore, India facility, leading to a significant stock price decline on February 27, 2025, after disappointing 2025 guidance. Investors are encouraged to contact Levi & Korsinsky before June 3, 2025, to learn about their rights.

**3. Viatris Says FDA Approves Octreotide Acetate, Clears MR-146 for Clinical Trials**
- Source: marketscreener.com | 20251218T133012 | Bullish | Relevance: 100%
- Viatris announced that the FDA has approved Octreotide Acetate, a generic version of SandostatinÂ®, used to treat acromegaly and neuroendocrine tumors. Additionally, the company received clearance to advance MR-146 into clinical trials for the treatment of chronic cough. These developments represent key regulatory milestones for Viatris's pipeline.

**4. Viatris secures four regulatory milestones across global pipeline**
- Source: Investing.com | 20251218T122756 | Bullish | Relevance: 100%
- Viatris Inc. announced four regulatory milestones, including a key FDA approval for a generic injectable medication for acromegaly and certain tumors, marking its fourth injectable FDA approval in 2025. The company also saw its New Drug Application for a low-dose estrogen weekly contraceptive patch accepted for review by the FDA and an Investigational New Drug application for a gene therapy candidate cleared. Additionally, regulatory authorities in Japan accepted its New Drug Application for pitolisant in obstructive sleep apnea syndrome.

**5. Viatris to Present at the 44th Annual J.P. Morgan Healthcare Conference**
- Source: PR Newswire | 20251217T120828 | Neutral | Relevance: 100%
- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, announced it will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026. The presentation and fireside chat will begin at 9 a.m. PT / 12 p.m. ET and will be available via live webcast and an archived version on the company's investor relations website.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $15 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 50.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 12.2% (-3.3%)
- Price (T.Rowe) Assoc: 7.3% (+6.7%)
- Blackrock Inc.: 7.1% (-1.1%)
- Davis Selected Advis: 6.0% (+4.5%)
- State Street Corpora: 4.8% (+0.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.14 indicates undervaluation relative to growth. Forward P/E 4.8x attractive for 7% earnings growth. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $13.8B |
| Beta | 0.83 |
| 52W Range | $6.85 - $12.68 |
| Short Interest | 2.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.14 |
| Forward P/E | 4.8 |
| Current P/E | 5.2 |
| YoY Growth | 6.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 5.9% to 2.8% (-3.0% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 0.2pp (needs >3.0% for momentum thesis). MRS_5 at 0.4% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). RSI overbought at 72, risk of mean reversion. OFD pattern: +DBH (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.83% (CS: 91) | Neutral |
| RSI_14 | 72.5 | Overbought |
| MACD Histogram | 0.07 | Bullish |
| vs SMA20 | 1.072x | Above |
| vs SMA50 | 1.117x | Above |
| vs SMA200 | 1.251x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $11.93
- **Stop Loss:** $11.31 (5.2% risk)
- **Target:** $12.55 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 1935
- **Position Value:** $23,084.55
- **Portfolio %:** 23.08%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-02-26 (Est: $0.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.62 | $0.67 | +8.5% |
| 2025Q2 | $0.56 | $0.62 | +11.6% |
| 2025Q1 | $0.49 | $0.50 | +1.6% |
| 2024Q4 | $0.57 | $0.54 | -5.6% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*